American Heart Journal
Volume 147, Issue 6 , Pages 956-965 , June 2004

Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors

  • Shelina M Jamal, BSc

      Affiliations

    • Divisions of Divisions of Cardiology and Clinical Epidemiology, Montreal, Quebec, Canada
    • ,
  • Mark J Eisenberg, MD, MPH

      Affiliations

    • Divisions of Divisions of Cardiology and Clinical Epidemiology, Montreal, Quebec, Canada
    • ,
  • Stavroula Christopoulos, MD

      Affiliations

    • Divisions of Endocrinology and Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Stavroula Christopoulos, MD, Division of Clinical Epidemiology, Jewish General Hospital/McGill University, 3755 Cote Ste-Catherine Rd/Suite A-118, Montreal, Quebec H3T 1E2, Canada.

Received 3 April 2003 ,Accepted 31 December 2003.

References 

  1. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 1995;333:1301–1307
  2. Available at: www.ims-global.com. Accessed June 28, 2002
  3. Availabel at: http://www.fda.gov/bbs/topics/. Accessed August 28, 2001
  4. Fuhrmans V. Bayer discloses higher death toll from Baycol. Wall Street J January 21, 2002;A10
  5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540
  6. Pasternak RC, Smith SC, Bairey-Merz CN, et al.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567–572
  7. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine. 1982;61:141–152
  8. Thompson DD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690
  9. Sauret JM. Rhabdomyolysis. Am Fam Physician. 2002;65:907–910
  10. Hino I, Akama H, Furuya T, et al.  Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum. 1996;39:1259–1261
  11. Farmer JA. Learning from the cerivastatin experience. Lancet. 2001;358:1383–1384
  12. Pfeffer MA, Keech A, Sacks FM, et al.  Safety and tolerability of pravastatin in long-term clinical trials (Pravastatin Pooling Project). Circulation. 2002;105:2341–2346
  13. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE study). N Engl J Med. 1996;335:1001–1009
  14. LIPID Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;1349–57
  15. WOSCOPS Study Group . A coronary primary prevention study of Scottish men aged 45–64 years (trial design). J Clin Epidemiol. 1992;45:849–860
  16. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)). Lancet. 1994;344:1383–1389
  17. Downs JR, Clearfield M, Tyroler HA, et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (results of AFCAPS/TexCAPS). JAMA. 1998;279:1615–1622
  18. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205–207
  19. Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia (the RIGHT study). Am J Cardiol. 1998;82:47–51J
  20. Ose L, Luurila O, Eriksson J, et al.  Efficacy and safety of cerivastatin, 0.2mg and 0.4mg, in patients with primary hypercholesterolemia (a multinational, randomized, double blind study). Curr Med Res Opin. 1999;15:228–240
  21. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 1999;84:497
  22. Available at: http://www.docguide.com/news/content.nsf/NewsPrint/. Accessed August 30, 2001
  23. Available at: http://www.docguide.com/dg.nsf/PrintPrint/. Accessed August 28, 2001
  24. Gemici G, Toprak A, Oktay A. Rhabdomyolysis due to cerivastastin monotherapy. Am J Med. 2001;110:742
  25. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430
  26. Corsini A, Bellosta S, Baetta R, et al.  New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428
  27. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors. Drugs. 1998;36(Suppl 3):72–82
  28. Walker JF. HMG CoA reductase inhibitors (current clinical experience). Drugs. 1988;36(Suppl 3):83–86
  29. Tobert JA. New developments in lipid-lowering therapy (the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase). Circulation. 1987;76:534–538
  30. MacDonald RH. Lipid-lowering drugs and atherosclerosis. In:  Brody TM editors. Human pharmacology (molecular to clinical. 3rd ed.). St. Louis: Mosby; 1998;p. 286–294
  31. Muck W, Ritter W, Ochmann K, et al.  Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharm Ther. 1997;35:255–260
  32. McTaggart F. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28–32B
  33. Von Keutz E, Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am J Cardiol. 1998;82:7J–11
  34. Flint OP, Masters BA, Gregg RE, et al.  Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145:91–98
  35. Rosenberg AD, Neuwirth MG, Kagen LJ, et al.  Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Analg. 1995;81:1089–1091
  36. Laaksonen R, Jokelainen K, Sahi T, et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Pharmacol Ther. 1995;57:62–66
  37. Folkers K, Langsjoen P, Willis R, et al.  Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87:8931–8934
  38. Ghirlanda G, Oradei A, Manto A, et al.  Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors (a double-blind, placebo-controlled study). J Clin Pharmacol. 1993;33:226–229
  39. Langsjoen PH, Langsjoen PH, Folker K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;15:521–523
  40. dePinieux G, Chariot P, Ammi-Said M, et al.  Lipid-lowering drugs and mitochondrial function (effects of HMG-CoA reductase inhibitors on serum Q10 and blood lactate/pyruvate ratio). Br J Clin Pharmacol. 1996;42:333–337
  41. Mabuchi H, Haba T, Tatami R, et al.  Effects of an inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A reductase on serum lipoprotein and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 1985;305:478–482
  42. Phillips PS, Haas RH, Bannykh S, et al.  Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–585
  43. Chariot P, Abadia R, Agnus D, et al.  Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109–110
  44. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet. 1989;2:1097–1098
  45. Abe K, Hirono N, Fujimura H, et al.  Co Q therapy in a patient with MELAS. Acta Neurologica Scand. 1991;83:356–359
  46. Sobreira C, Hirano M, Shanske S, et al.  Mitichondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238–1243
  47. Ogasawara S, Engel AG, Frens D, et al.  Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379–2382
  48. Ogasawara S, Nishikawa Y, Yorifuji S, et al.  Improvement of abnormal pyruvate metabolism and cardiac conduction defect with CoQ10 in Kearns-Sayre syndrome. Neurology. 1985;5:372–377
  49. Chariot P, Abadia R, Agnus D, et al.  Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109–110
  50. Federman DG, Hussain F, Walters JB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J. 2001;94:1023–1026
  51. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52:1639–1644
  52. Pierce RL, Wysowki DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71–75
  53. Maltz HC, Baolog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother. 1999;33:1176–1179
  54. Guijarro C, Blanco-Colio LM, Ortego M, et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490–500
  55. Knapp AC, Huang J, Starling G, et al.  Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152:217–227
  56. Nakagawa H, Mutoh T, Kumano T, et al.  Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts. FEBS Letters. 2001;508:53–56
  57. Macaluso M, Russo G, Cinti C, et al.  Ras family genes (an interesting link between cell cycle and cancer). J Cell Physiol. 2002;192:125–130
  58. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002;128:159–168
  59. Feller DR, Kamanna VS, Newman HA, et al.  Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers. J Med Chem. 1987;30:1265–1267
  60. Pierno S, De Luca A, Tricarico D, et al.  Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle. Pharmacol Toxicol. 1992;71:325–329
  61. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57:357–364
  62. Martinez-Castelao A, Grinyo JM, Gil-Vernet S, et al.  Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplant Proc. 2002;34:398–400
  63. Bramow S, Ott P, Thomsen NF, et al.  Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cylosporine A and sirolimus. Pharmacol Toxicol. 2001;89:133–139
  64. Smith PF, Eydelloth RS, Grossman SJ, et al.  HMG-CoA reductase inhibitor-induced myopathy in the rat (cyclosporine A interaction and mechanism studies). J Pharmacol Exp Ther. 1991;257:1225–1235
  65. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia (an appraisal of their efficacy and safety). Eur Heart J. 1995;16:5–13
  66. Shek A. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908–917
  67. Prueksantanont T, Subramanian R, Fang X, et al.  Glucuronidation of statins in animals and humans. Drug Metab Dispos. 2002;30:505–512
  68. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology. 1991;41:1159–1160
  69. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71–75
  70. Pasternak R, Smith SC, Bairey-Merz CN, et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. 2002;106:1024–1028
  71. Vu D, Murty M, McMorran M. Statins (rhabdomyolysis and myopathy). Can Adverse Drug React Newsletter. 2002;12:1–3
  72. Baker SK, Tarnopolsky MA. Statin myopathies (pathophysiologic and clinical perspectives). Clin Invest Med. 2001;24:258–272
  73. Sica DA, Gehr TW. Rhabdomyolysis and statin therapy (relevance to the elderly). Am J Geriatr Cardiol. 2002;11:48–55
  74. Willis RA, Folkers K, Tucker JL, et al.  Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A. 1990;87:8928–8930

☆ Dr. Eisenberg is a Physician-Scientist of the Quebec Foundation for Health Research.

PII: S0002-8703(04)00059-6

doi: 10.1016/j.ahj.2003.12.037

American Heart Journal
Volume 147, Issue 6 , Pages 956-965 , June 2004

Article Tools

* Image Usage & Resolution